Formulated for androgenetic alopecia to target hormonal conversion and support hair growth maintenance.
Mechanism of Action
Finasteride competitively inhibits the Type II 5-alpha reductase enzyme. This prevents the conversion of testosterone to dihydrotestosterone, the hormone responsible for male pattern hair loss.
Route of Administration
Oral
Onset Time
3–6 months
Duration
24 hours
Contraindications
Pregnancy, Hypersensitivity to finasteride, Pediatric use, Use in females
Severe Adverse Events
Male breast cancer, Depression, Severe allergic reaction — requires immediate medical attention
Information related to Finpecia is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
